Gene Review:
PDE4A - phosphodiesterase 4A, cAMP-specific
Homo sapiens
Synonyms:
DPDE2, PDE4, PDE46, cAMP-specific 3',5'-cyclic phosphodiesterase 4A
Cherry,
Thompson,
Pho,
Lipworth,
Renau,
Ahlström,
Pekkinen,
Huttunen,
Lamberg-Allardt,
Marx,
Tassabehji,
Heer,
Hüttenbrink,
Szelenyi,
Kanda,
Watanabe,
Narita,
Murata,
Shimizu,
Nakagawa,
Sugiyama,
Inui,
Hiramoto,
Tagawa,
Ghavami,
Hirst,
Novak,
Pryzwansky,
Madden,
Bartsch,
Bartlick,
Ivell,
Chen,
Chen,
Xie,
Zhu,
- Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells. Ahlström, M., Pekkinen, M., Huttunen, M., Lamberg-Allardt, C. Biochem. Pharmacol. (2005)
- Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors. Oger, S., Méhats, C., Barnette, M.S., Ferré, F., Cabrol, D., Leroy, M.J. Biol. Reprod. (2004)
- A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells. Narita, M., Murata, T., Shimizu, K., Nakagawa, T., Sugiyama, T., Inui, M., Hiramoto, K., Tagawa, T. Oncol. Rep. (2007)
- Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Richter, W., Jin, S.L., Conti, M. Biochem. J. (2005)
- Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. Ekholm, D., Hemmer, B., Gao, G., Vergelli, M., Martin, R., Manganiello, V. J. Immunol. (1997)
- Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4). Bivalacqua, T.J., Champion, H.C., Rajasekaran, M., Sikka, S.C., Kadowitz, P.J., Doherty, P.C., Hellstrom, W.J. J. Urol. (1999)
- Selective Phosphodiesterase (PDE)-4 Inhibitors : A Novel Approach to Treating Memory Deficit? Ghavami, A., Hirst, W.D., Novak, T.J. Drugs in R&D. (2006)
- The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges. Renau, T.E. Current opinion in investigational drugs (London, England : 2000) (2004)
- Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Lehnart, S.E., Wehrens, X.H., Reiken, S., Warrier, S., Belevych, A.E., Harvey, R.D., Richter, W., Jin, S.L., Conti, M., Marks, A.R. Cell (2005)
- Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Baillie, G.S., Houslay, M.D. Curr. Opin. Cell Biol. (2005)
- An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics. Willoughby, D., Wong, W., Schaack, J., Scott, J.D., Cooper, D.M. EMBO J. (2006)
- A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Card, G.L., Blasdel, L., England, B.P., Zhang, C., Suzuki, Y., Gillette, S., Fong, D., Ibrahim, P.N., Artis, D.R., Bollag, G., Milburn, M.V., Kim, S.H., Schlessinger, J., Zhang, K.Y. Nat. Biotechnol. (2005)
- Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294. Gale, D.D., Hofer, P., Spina, D., Seeds, E.A., Banner, K.H., Harrison, S., Douglas, G., Matsumoto, T., Page, C.P., Wong, R.H., Jordan, S., Smith, F., Banik, N., Halushka, P.V., Cavalla, D., Rotshteyn, Y., Kyle, D.J., Burch, R.M., Chasin, M. Pulmonary pharmacology & therapeutics. (2003)
- Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids. Marx, D., Tassabehji, M., Heer, S., Hüttenbrink, K.B., Szelenyi, I. Pulmonary pharmacology & therapeutics. (2002)
- Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lipworth, B.J. Lancet (2005)
- Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Miotla, J.M., Teixeira, M.M., Hellewell, P.G. Am. J. Respir. Cell Mol. Biol. (1998)
- Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Spina, D. Drugs (2003)
- Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Erdogan, S., Houslay, M.D. Biochem. J. (1997)
- Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. Sullivan, M., Rena, G., Begg, F., Gordon, L., Olsen, A.S., Houslay, M.D. Biochem. J. (1998)
- Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Saldou, N., Obernolte, R., Huber, A., Baecker, P.A., Wilhelm, R., Alvarez, R., Li, B., Xia, L., Callan, O., Su, C., Jarnagin, K., Shelton, E.R. Cell. Signal. (1998)
- Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Baillie, G.S., MacKenzie, S.J., McPhee, I., Houslay, M.D. Br. J. Pharmacol. (2000)
- Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Manning, C.D., Burman, M., Christensen, S.B., Cieslinski, L.B., Essayan, D.M., Grous, M., Torphy, T.J., Barnette, M.S. Br. J. Pharmacol. (1999)
- Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines. Pooley, L., Shakur, Y., Rena, G., Houslay, M.D. Biochem. J. (1997)
- Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Landells, L.J., Szilagy, C.M., Jones, N.A., Banner, K.H., Allen, J.M., Doherty, A., O'Connor, B.J., Spina, D., Page, C.P. Br. J. Pharmacol. (2001)
- AKAP3 selectively binds PDE4A isoforms in bovine spermatozoa. Bajpai, M., Fiedler, S.E., Huang, Z., Vijayaraghavan, S., Olson, G.E., Livera, G., Conti, M., Carr, D.W. Biol. Reprod. (2006)
- Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. MacKenzie, S.J., Houslay, M.D. Biochem. J. (2000)
- Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis. Richter, W., Unciuleac, L., Hermsdorf, T., Kronbach, T., Dettmer, D. Cell. Signal. (2001)
- Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram. Chen, J.C., Chen, J.Q., Xie, Q.M., Zhu, Y.L. Acta Pharmacol. Sin. (2004)
- Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse. Cherry, J.A., Thompson, B.E., Pho, V. Biochim. Biophys. Acta (2001)
- Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Bolger, G.B., Baillie, G.S., Li, X., Lynch, M.J., Herzyk, P., Mohamed, A., Mitchell, L.H., McCahill, A., Hundsrucker, C., Klussmann, E., Adams, D.R., Houslay, M.D. Biochem. J. (2006)
- Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition. McPhee, I., Yarwood, S.J., Scotland, G., Huston, E., Beard, M.B., Ross, A.H., Houslay, E.S., Houslay, M.D. J. Biol. Chem. (1999)
- Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Heystek, H.C., Thierry, A.C., Soulard, P., Moulon, C. Int. Immunol. (2003)
- Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293beta2 cells and cardiac myocytes. Li, X., Huston, E., Lynch, M.J., Houslay, M.D., Baillie, G.S. Biochem. J. (2006)
- Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. Kanda, N., Watanabe, S. Biochem. Pharmacol. (2001)
- Phosphodiesterase 4 inhibition synergizes with relaxin signaling to promote decidualization of human endometrial stromal cells. Bartsch, O., Bartlick, B., Ivell, R. J. Clin. Endocrinol. Metab. (2004)
- A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. Asirvatham, A.L., Galligan, S.G., Schillace, R.V., Davey, M.P., Vasta, V., Beavo, J.A., Carr, D.W. J. Immunol. (2004)
- Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. Manning, C.D., McLaughlin, M.M., Livi, G.P., Cieslinski, L.B., Torphy, T.J., Barnette, M.S. J. Pharmacol. Exp. Ther. (1996)
- L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Valente, E.G., Vernet, D., Ferrini, M.G., Qian, A., Rajfer, J., Gonzalez-Cadavid, N.F. Nitric Oxide (2003)
- Type 4A cAMP-specific phosphodiesterase is stored in granules of human neutrophils and eosinophils. Pryzwansky, K.B., Madden, V.J. Cell Tissue Res. (2003)